Related Experiment Video
Updated: Jan 31, 2026

Dosage-Adjusted Resistance Training in Mice with a Reduced Risk of Muscle Damage
Published on: August 31, 2022
Olaparib: A tale of two dosage forms
1The University of Chicago Medicine, Chicago, IL 60637, USA.
Abstract:
Olaparib is the first poly(ADP-ribose) polymerase (PARP) inhibitor approved by the Food and Drug Administration (FSA), with three approvals in two different cancer types. The original dosage form of olaparib was a 50 mg capsule, requiring 16 capsules per day for patients at full dose therapy which prompted development of a tablet dosage form with improved bioavailability. Herein, major trials for olaparib are reviewed and the two dosage forms are compared from a pharmacokinetic and clinical perspective.
More Related Videos
Related Concept Videos
Dosage Regimen: Multiple Oral Dosage
Dosage Compensation
In addition to sexual development, the X chromosome has genes involved in autosomal functions such as brain development and the immune system. Therefore, males and females with distinct numbers of X chromosomes will...
Dosage Regimen: Individualization
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimens: Designs and Approaches

